Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Drug

Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease

Fineline Cube Mar 17, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...

Company Drug

Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment

Fineline Cube Mar 17, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...

Company

Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Fineline Cube Mar 16, 2025

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...

Company

Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation

Fineline Cube Mar 16, 2025

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...

Digital

DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation

Fineline Cube Mar 15, 2025

The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...

Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Company Drug

Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Mar 14, 2025

Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...

Company Deals

Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab

Fineline Cube Mar 14, 2025

CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an...

Company Deals

BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial

Fineline Cube Mar 14, 2025

China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...

Company Deals Hospital

Shanghai Fosun Pharmaceutical Transfers Unicorn II Holdings Stake to Warburg Pincus Subsidiary

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to transfer...

Company Deals

Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins

Fineline Cube Mar 14, 2025

Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial

Fineline Cube Mar 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced receiving approval from the US Food and...

Company Medical Device

Gaush Meditech’s ANTERION Ophthalmic Detector Receives NMPA Market Approval

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company Drug

Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA

Fineline Cube Mar 14, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...

Company Drug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Fineline Cube Mar 14, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...

Company Drug

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...

Company Drug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Fineline Cube Mar 14, 2025

China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...

Company Drug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Fineline Cube Mar 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Posts pagination

1 … 235 236 237 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.